Top 5 worldwide oncology products by market share 2017 and 2024
This statistic displays the top oncology products worldwide by projected market share for 2024, and their market shares in 2017. Cancer drug Opdivo from Bristol-Myers Squibb and Ono Pharmaceutical is expected to keep its position with a market share of five percent.
Top oncology products
Oncological products generate a significant proportion of their revenue in the United States and in Europe. In 2012, oncology spending totaled nearly 50 billion U.S. dollars in the United States and 22 billion U.S. dollars in the leading five EU-countries. Oncology is among the top therapy classes in the pharmaceutical market.
Among the top oncology products in 2017 were Keytruda and Opdivo, generating 3.8 and 5.7 billion U.S. dollars on the worldwide market. Top cancer drug Rituxan is marketed by Roche and is used to treat diseases such as lymphomas, leukemias, transplant rejections, and autoimmune disorders. Bevacizumab, marketed as Avastin also under Roche, is used to slow down the growth rate of new blood vessels. It can be used to treat cancers such as those originating in the colorectum, lung, breast, or kidney. Roche has a stronghold on the global oncology market. In 2017, Roche maintained a share of over 26 percent of the market but is expected to drop to some 12 percent of the market in 2024. Roche or Hoffman-La Roche is a Swiss company that was founded in 1896. The company focuses primarily on pharmaceutical products and diagnostics. Roche generated more than 53 billion Swiss francs in revenue in 2017, making it one of the most successful biotech and pharmaceutical companies in the world.
Top oncology products
Oncological products generate a significant proportion of their revenue in the United States and in Europe. In 2012, oncology spending totaled nearly 50 billion U.S. dollars in the United States and 22 billion U.S. dollars in the leading five EU-countries. Oncology is among the top therapy classes in the pharmaceutical market.
Among the top oncology products in 2017 were Keytruda and Opdivo, generating 3.8 and 5.7 billion U.S. dollars on the worldwide market. Top cancer drug Rituxan is marketed by Roche and is used to treat diseases such as lymphomas, leukemias, transplant rejections, and autoimmune disorders. Bevacizumab, marketed as Avastin also under Roche, is used to slow down the growth rate of new blood vessels. It can be used to treat cancers such as those originating in the colorectum, lung, breast, or kidney. Roche has a stronghold on the global oncology market. In 2017, Roche maintained a share of over 26 percent of the market but is expected to drop to some 12 percent of the market in 2024. Roche or Hoffman-La Roche is a Swiss company that was founded in 1896. The company focuses primarily on pharmaceutical products and diagnostics. Roche generated more than 53 billion Swiss francs in revenue in 2017, making it one of the most successful biotech and pharmaceutical companies in the world.
